EHA 2023 | Unmet needs in polycythemia vera: improving symptoms & qualify of life
Haifa Kathrin Al-Ali, MD, Martin Luther University of Halle-Wittenberg, Halle, Germany, discusses the unmet needs in the field of polycythemia vera (PV). Dr Al-Ali explains that patient quality of life (QoL) is a key focus, as many patients who achieve suboptimal response are kept on traditional treatments, rather than being switched to newer drugs including ruxolitinib. Dr Al-Ali also discusses the need to pay attention to cardiovascular risks in patients, and the benefits of newer treatments in regard to the risk of transformation of PV into acute myeloid leukemia (AML) or secondary myelofibrosis (MF). This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research support from Novartis, Bristol Myers Squibb and Incyte,
participating on a scientific advisory board for Novartis, Bristol Myers Squibb, Abbvie, SGK, Blue Print, AOP Pharma
travel grant from Bristol Myers Squibb and Abbvie
